What’s It About?
With Pivotal Approvals and Mounting Investment in MASH, This Summit is Your Comprehensive Guide to Preclinical, Translational, Clinical and Regulatory MASH Drug Development.
MASH is entering a new era. Despite significant investment in MASH R&D in the past many of the attempts were met with major setbacks and high-profile failures. Now the tide is turning with Madrigal’s approval, six late-stage assets in phrase 3 and a plethora of assets in phase 1-2.
The 8th MASH Drug Development Summit unites 120+ industry leaders to address the most pressing challenges in MASH and metabolic diseases. Harnessing FGF21s, THR-β Agonists, GLP-1 Agonists, FXR & PPAR Agonists to propel your MASH therapeutic pipelines. This is your opportunity to access cutting-edge R&D insights that can super-charge your end-to-end metabolic development strategy.
The 8th annual event will return to Boston this September 2024 to allow you to overcome barriers in development and commercialization to ensure approval, access and the adoption of novel NASH therapies. Providing solutions to key challenges from patient recruitment, endpoints, placebo response and combatting fibrosis.
Top 5 Takeaways
Delve into preclinical anti-fibrotic developments and their impact on ELF and PRO-C3 biomarkers and how to improve fibrosis replication with Pfizer and AstraZeneca
Accelerate your clinical trial design by optimizing cirrhosis, MASH and fibrosis targets in trials with AstraZeneca and 89Bios
Examine how GLP-1s can be leveraged in MASH to combat the disease drivers with Gilead, Altimmune and Seal Rock Therapeutics
Explore how the regulatory field is shifting and learn how to navigate regulatory approval with Madrigal and AstraZeneca
Leverage AI techniques and real world evidence to integrate data, harmonize predictions and identify future trends for MASH with Merck and AstraZeneca
Who Will You Meet?
Connect with senior biopharma leaders from:
...and more
What Your Peers Have to Say
"The meeting was an excellent conference. It was a highly informative and interactive meeting. The speakers presented cutting edge approaches for novel treatments for obesity and NASH. There was plenty of time for discussions and networking” CSO, Mitotherapeutix
“Good selection of talks covering the latest data and trends in MASH and obesity. Good speakers. Small intimate setting, opportunities for networking’’ Senior Director, Paratus Sciences
